Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics/pharmacodynamics of a single subcutaneous dose of Vasomera (PB1046) in adults with stage 1 o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Vasomera (PB1046)

Snippet

Sponsor: PhaseBio Pharmaceuticals Inc. | Conditions: Essential Hypertension | Phase 1 | Status: COMPLETED